Bill
HF 4349
Provisions governing hospital reimbursement for biological products to treat rare diseases modified.
2025-2026 Regular Session
Introduced by Kristin Bahner and 4 co-sponsors
Minnesota bill HF 4349 modifies hospital reimbursement rates for biological products treating rare diseases, affecting patient access and healthcare costs.
Introduction and first reading, referred to Health Finance and Policy